Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

ctDNA-MRD-Guided Aumolertinib-Based Adjuvant Therapy for Resected EGFR-Mutant Non-Small Cell Lung Cancer: A Real-World Interventional Study

NCT07873086 is registered in ClinicalTrials.gov with Peking University People's Hospital as lead sponsor.

NCT NCT07873086
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07873086 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
ctDNA-MRD-Guided Aumolertinib-Based Adjuvant Therapy for Resected EGFR-Mutant Non-Small Cell Lung Cancer: A Real-World Interventional Study
Lead sponsor
Peking University People's Hospital
Phase
Not applicable
Overall status
Not yet recruiting
Start date
November 1, 2026
Completion date
October 1, 2033
Enrollment
50 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

non-small cell lung cancer